DK1392285T3 - Lægemiddel indeholdende en effektor for glutathion-metabolismen sammen med alfa-liponsyre til brug ved nyreerstatningsterapi - Google Patents

Lægemiddel indeholdende en effektor for glutathion-metabolismen sammen med alfa-liponsyre til brug ved nyreerstatningsterapi

Info

Publication number
DK1392285T3
DK1392285T3 DK02747189T DK02747189T DK1392285T3 DK 1392285 T3 DK1392285 T3 DK 1392285T3 DK 02747189 T DK02747189 T DK 02747189T DK 02747189 T DK02747189 T DK 02747189T DK 1392285 T3 DK1392285 T3 DK 1392285T3
Authority
DK
Denmark
Prior art keywords
effector
alpha
lipoic acid
replacement therapy
drug containing
Prior art date
Application number
DK02747189T
Other languages
English (en)
Inventor
Michael Taeger
Gerhard Fries
Dieter Koegst
Siegfried Ansorge
Original Assignee
Serumwerk Bernburg Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serumwerk Bernburg Ag filed Critical Serumwerk Bernburg Ag
Application granted granted Critical
Publication of DK1392285T3 publication Critical patent/DK1392285T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02747189T 2001-05-28 2002-05-24 Lægemiddel indeholdende en effektor for glutathion-metabolismen sammen med alfa-liponsyre til brug ved nyreerstatningsterapi DK1392285T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10125883A DE10125883A1 (de) 2001-05-28 2001-05-28 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
PCT/DE2002/001991 WO2002096414A1 (de) 2001-05-28 2002-05-24 Arzneimittel enthaltend einen effektor des glutathionmetabolismus zusammen mit alpha-liponsäure im rahmen der nierenersatztherapie

Publications (1)

Publication Number Publication Date
DK1392285T3 true DK1392285T3 (da) 2005-06-13

Family

ID=7686362

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02747189T DK1392285T3 (da) 2001-05-28 2002-05-24 Lægemiddel indeholdende en effektor for glutathion-metabolismen sammen med alfa-liponsyre til brug ved nyreerstatningsterapi

Country Status (17)

Country Link
US (1) US7531567B2 (da)
EP (1) EP1392285B1 (da)
JP (1) JP4245926B2 (da)
CN (1) CN100435793C (da)
AR (1) AR034336A1 (da)
AT (1) ATE288750T1 (da)
BR (1) BR0209732A (da)
CA (1) CA2446673C (da)
DE (3) DE10125883A1 (da)
DK (1) DK1392285T3 (da)
ES (1) ES2237683T3 (da)
HK (1) HK1063606A1 (da)
MX (1) MXPA03010833A (da)
PE (1) PE20030090A1 (da)
PT (1) PT1392285E (da)
RU (1) RU2285525C2 (da)
WO (1) WO2002096414A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
DE10258239A1 (de) * 2002-12-13 2004-06-24 Degussa Ag Formulierung enthaltend alpha-Liponsäure(-Derivate) als alleinigen Wirkstoff bei nichtchronischen alkoholinduzierten Intoxikationen
DE10303229B4 (de) * 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
DE10360954B3 (de) * 2003-12-23 2005-08-18 Esparma Gmbh Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen
AU2005309502B2 (en) * 2004-11-24 2011-11-17 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
PT2638915T (pt) * 2008-07-18 2017-01-10 A1M Pharma Ab Utilização médica da alfa 1-microglobulina antioxidante e eliminadora de radicais
RU2011124739A (ru) * 2008-12-01 2013-01-10 Инваск Терапьютикс, Инк. Композиции, содержащие ингибиторы системы ренин-ангиотензин альдостерона и соединения липоевой кислоты, и их применение для лечения заболеваний, связанных с системой ренин-ангиотензин альдостерона
RU2530601C2 (ru) * 2012-10-05 2014-10-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибитор образования цинк-зависимых димеров бета-амилоида
CN106955270B (zh) * 2017-04-14 2018-04-27 黑龙江中桂制药有限公司 一种盐酸氨溴索口服溶液及其制备方法与新用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530761A1 (de) 1985-08-28 1987-03-05 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung
DE3804858A1 (de) * 1988-02-17 1989-08-31 Thomae Gmbh Dr K Mittel gegen hyperurikaemie
ES2115589T3 (es) 1989-11-09 1998-07-01 Asta Medica Ag Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa.
HU208949B (en) 1989-12-22 1994-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 4-trans-/4-isopropyliden-amino/-cyclohexanol
ATE162715T1 (de) 1991-07-05 1998-02-15 Asta Medica Ag Verwendung von schwefel enthaltenden carbonsäuren zur bekämpfung von pathophysiologisch bedingten erregungsstörungen
DE4343592C2 (de) 1993-12-21 1998-04-16 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems
DE4420102A1 (de) * 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
DE4439477C2 (de) 1994-11-08 1999-10-21 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
JP3670016B2 (ja) 1994-12-16 2005-07-13 ワーナー−ランバート・カンパニー カプレットをカプセル内に封入する方法及びかかる方法により得ることができる固体剤形
WO1996033704A1 (fr) 1995-04-26 1996-10-31 Taisho Pharmaceutical Co., Ltd. Preparation pour administration orale
HUP9601442A3 (en) 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
DE19806354B4 (de) * 1998-02-10 2004-09-16 Bdd Group Holding Ag Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
DE19933148A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette

Also Published As

Publication number Publication date
BR0209732A (pt) 2004-09-14
ES2237683T3 (es) 2005-08-01
RU2285525C2 (ru) 2006-10-20
RU2003137772A (ru) 2005-05-27
HK1063606A1 (en) 2005-01-07
CA2446673A1 (en) 2002-12-05
DE10125883A1 (de) 2002-12-12
PT1392285E (pt) 2005-06-30
US7531567B2 (en) 2009-05-12
MXPA03010833A (es) 2004-11-22
JP4245926B2 (ja) 2009-04-02
PE20030090A1 (es) 2003-04-01
US20040127550A1 (en) 2004-07-01
WO2002096414A1 (de) 2002-12-05
ATE288750T1 (de) 2005-02-15
DE10292279D2 (de) 2004-05-06
DE50202227D1 (de) 2005-03-17
EP1392285A1 (de) 2004-03-03
AR034336A1 (es) 2004-02-18
JP2004535410A (ja) 2004-11-25
CN100435793C (zh) 2008-11-26
EP1392285B1 (de) 2005-02-09
CN1531429A (zh) 2004-09-22
CA2446673C (en) 2010-12-14

Similar Documents

Publication Publication Date Title
GB0206033D0 (en) Compounds useful in therapy
PL377656A1 (pl) Ligandy Ó2Ű do różnych zastosowań farmaceutycznych
EP1648362A4 (en) FILM CONTAINING THERAPEUTIC AGENTS
EP1552269A4 (en) FORMOL-AMMONIUM SALT COMPLEXES FOR STABILIZING GLOBULES
GB2394894B (en) New use for pharmaceutical composition
PT1633388E (pt) Formulações proteicas líquidas estabilizadas em recipientes farmacêuticos
HK1096895A1 (en) Cryogranulation and storage method for active pharmaceutical agents
PL359321A1 (en) New salt perindopryl and pharmaceutical composunds containing it
HK1086492A1 (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'- fluoroanilino)phenylacetic acid
DK1392285T3 (da) Lægemiddel indeholdende en effektor for glutathion-metabolismen sammen med alfa-liponsyre til brug ved nyreerstatningsterapi
ZA200703056B (en) 4-[(phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1543840A4 (en) AGENTS FOR IMPROVING THE ABSORPTION OF PHARMACEUTICAL PRODUCTS
AU2003291642A8 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2003260095A8 (en) Methods for recruiting patients for clinical studies
AU2003302320A8 (en) Seterocyclic quinones as pharmaceutical agents
PL375074A1 (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0223272D0 (en) A protein involved in therapy
AU2003219892A8 (en) Ion powered platform
AU2002317683A1 (en) Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
PT1517679E (pt) Derivados do ácido benzóico substituído na posição orto para o tratamento de resistência à insulina
PL370175A1 (en) Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes
IL163762A0 (en) Ophthalmic solutions containing tetrazole derivatives
GB0204683D0 (en) Pharmaceutical salts
GB0206708D0 (en) Pharmaceutical salts
GB0224013D0 (en) A protein involved in therapy